Nitto Denko Avecia to debut its expanded API plant next month

Nitto Denko Avecia to open expanded API plant in Milford, MA., next month.

Nitto Denko Avecia, a CMO, said it will open its expanded oligonucleotide API manufacturing facility next month in Milford, Massachusetts. 

The maker of oligonucleotides, which are DNA or RNA molecules used in a variety of applications in genetic testing, research, and forensics, said it expanded the plant by 20,000 square feet for manufacturing and office space. The facility will be capable of producing oligonucleotide API capacity up to 1.8 molecular weight (mol).

The company said the expanded capacity will make the plant the largest oligonucleotide API manufacturing site in the world.

"This expansion will help Avecia's clients to receive timely oligonucleotide API to advance their drug development programs in clinical trials as planned,” Detlef Rethage, Avecia’s president, said in a statement. "Avecia takes pride that our engineers have introduced novel technology, executed this expansion in record time, and in close collaboration with A/Z Corporation to ensure the timely supply of novel oligonucleotide therapeutics.”

The company has added more than 120 jobs in Massachusetts in the last year and is currently looking to hire a total of 50 more positions in that state as well as at its operations in Ohio and California. 

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.